Krystal Biotech, Inc. KRYS 深 滬
已收盤 12-12 16:00:00 美东时间
244.65
-2.125
-0.86%
華盛通- 最 高248.595
- 今 開246.97
- 成交量 33.40万股
- 最 低 242.58
- 昨 收 246.775
- 總市值 70.81亿
- 52周最高 248.595
- 市盈率 靜 81.60
- 換手率 1.15%
- 52周最低 122.80
- 委 比 33.54%
- 總股本 2894.30万
- 歷史最高 248.595
- 量 比 0.79
- 振 幅 2.44%
- 歷史最低 8.03
- 每 手 1
- 風險率 24.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years...
12-05 05:00
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) announced its participation in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and CEO, will engage in a fireside chat and host investor meetings. A live webcast of the presentation will be available starting at 10:00 am ET and later posted on the Company’s website. Krystal Biotech is a global biotechnology company specializing in genetic medicines, with...
11-26 13:00
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $220
Chardan Capital analyst Geulah Livshits maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $216 to $220.
11-04 21:23
Krystal Biotech Q3 EPS $2.66 Beats $1.03 Estimate, Sales $97.800M Beat $93.186M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $1.03 by 158.5 percent. This is a 192.31 percent increase over earnings of $0.91 per share from
11-03 20:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Earnings Preview For TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) will release its quarterly earnings report on Mon...
11-01 03:01
Krystal Biotech Unit Launches VYJUVEK In Japan For Treatment Of Dystrophic Epidermolysis Bullosa; VYJUVEK Priced At ¥2,955,232.7 Per Unit In Japan
Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan for
10-22 21:14
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
快讯 | Krystal Biotech Inc：美国银行环球研究将目标价从182美元上调至255美元
Krystal Biotech Inc : BofA Global Research Raises Price Objective to $255 From ...
10-17 18:29
